NLRP3 and Alzheimer disease: The neuroprotective effects of 2 mg/kg RRx-001 administration to Alzheimer's disease (AD), which has been linked to aberrant NLRP3 activation, were evaluated via intraperitoneal injection once weekly for 3 months in aged (21- to 24-month-old) triple transgenic Alzheimer’s disease model (3×Tg-AD) mice and control non-transgenic (NonTg) mice.